documentation and ensure compliance with regulatory expectations.

4. Accountability

Head – Gel Manufacturing and Head – Quality Assurance are accountable for ensuring implementation and compliance with this SOP.

5. Procedure

5.1 Polymer Pre-Selection Criteria

1. Compile a list of pharmaceutically acceptable bio-adhesive polymers from pharmacopeial and GRAS sources.
2. Ensure the selected polymers meet regulatory acceptability for the intended route of administration.
3. Consider compatibility with APIs, solvents, preservatives, and other formulation components.

5.2 Evaluation Parameters

1. Evaluate candidate polymers based on the following properties:
   • Bio-adhesive strength (using texture analyzer or modified balance method)
   • Swelling index
   • Viscosity behavior
   • Mucoadhesive time or retention time
   • Chemical compatibility with API and excipients
   • Effect on drug release rate
2. Perform adhesion studies on relevant biological substrates (e.g., mucosa, skin tissue).

5.3 Laboratory Trials

1. Prepare experimental gel formulations incorporating different concentrations of each polymer (typically 0.5% to 5% w/w).
2. Evaluate preliminary formulations for physical appearance, stability, spreadability, and adhesiveness.
3. Shortlist the most promising polymers based on performance results.

5.4 Final Selection and Documentation

1. Document results of all trials and evaluations in the Polymer Screening Log (Annexure-1).
2. Summarize analytical and physical performance data in the Polymer Evaluation Summary (Annexure-2).
3. Select the most suitable polymer for the final formulation and record justification in the Final Selection Report (Annexure-3).

5.5 Regulatory and Safety Considerations

1. Ensure polymer specifications align with pharmacopoeial standards (IP/USP/Ph. Eur.).
2. Refer to safety data sheets and toxicological databases for human usage data.
3. Avoid polymers with known allergens or sensitizers for dermal or mucosal use.

6. Abbreviations

• API: Active Pharmaceutical Ingredient
• GRAS: Generally Recognized As Safe
• QA: Quality Assurance
• IP: Indian Pharmacopoeia
• USP: United States Pharmacopeia
• Ph. Eur.: European Pharmacopoeia

7. Documents

1. Polymer Screening Log – Annexure-1
2. Polymer Evaluation Summary – Annexure-2
3. Final Selection Report – Annexure-3

8. References

• ICH Q8 – Pharmaceutical Development
• USP General Chapter <1004> – Bioadhesive Drug Delivery Systems
• WHO Technical Series on Mucosal Drug Delivery

9. SOP Version

Version: 2.0

10. Approval Section

	Prepared By	Checked By	Approved By
Signature
Date
Name
Designation	Formulation Scientist	QA Executive	Head – Manufacturing
Department	Gel Manufacturing	Quality Assurance	Manufacturing

11. Annexures

Annexure-1: Polymer Screening Log

Polymer Name	Batch No.	Concentration (%)	Appearance	Initial Viscosity

Annexure-2: Polymer Evaluation Summary

Polymer	Bio-Adhesion Score	Stability (days)	Release Profile	Remarks

Annexure-3: Final Selection Report

Selected Polymer
Concentration
Justification
Approved By

Revision History

Revision Date	Revision No.	Change Description	Reason	Approved By
12/06/2022	1.0	Initial version	New SOP	QA Manager
09/06/2025	2.0	Added annexures and evaluation criteria	Updated for R&D integration	QA Manager